Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study

被引:24
|
作者
Kanarek, Norma F. [1 ,2 ]
Kanarek, Marty S. [3 ,4 ]
Olatoye, Dare [5 ]
Carducci, Michael A. [6 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[4] Univ Wisconsin Madison, Nelson Inst Environm Studies, Madison, WI 53726 USA
[5] Johns Hopkins Sch Med, Baltimore, MD 21205 USA
[6] Johns Hopkins Sch Med, Dept Oncol Urol Oncol, Baltimore, MD USA
来源
TRIALS | 2012年 / 13卷
关键词
Justice; Beneficence; Respect for persons; Clinical trials; Clinical trial accrual; Prostate cancer; Barriers to clinical trials; Disparities; Framework; PROSTATE-SPECIFIC ANTIGEN; COMPREHENSIVE CANCER CENTER; INFORMED-CONSENT; RANDOMIZED-TRIALS; PATIENT INTEREST; DECISION-MAKING; BREAST-CANCER; WORKING GROUP; IMPACT; ENROLLMENT;
D O I
10.1186/1745-6215-13-237
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Enrollment in interventional therapeutic clinical trials is a small fraction of all patients who might participate given reasonable access. Methods: A hierarchical approach is utilized in measuring staged participation from trial availability to patient enrollment. Our framework suggests that concern for justice comes in the design and eligibility criteria for clinical trials; attention to beneficence is given in the eligibility and physician triage stages. The remaining four stages rely on respect for persons. An example is given where reasons for nonparticipation or barriers to participation in prostate cancer clinical trials are examined within the framework. In addition, medical oncology patients with an initial six month consultation are tracked from one stage to the next by race using the framework to assess participation comparability. Results: We illustrated seven transitions from being a patient to enrollment in a clinical trial in a small study of prostate cancer cases who consulted SKCCC Medical Oncology Department in early 2010. Pilot data suggest transition probabilities as follows: 65% availability, 84% eligibility, 92% patient triage, 89% trials discussed, 45% patient interested, 63% patient consented, and 92% patient enrolled. The average transition probability was 77.7%. The average transition probability, patient-trial-fit was 50%; opportunity was 51%, and acceptance was 66.7%. Trial availability, patient interest and patient consented were three transitions that were below the average; none were statistically significant. Conclusions: The framework may serve to streamline comprehensive reporting of clinical trial participation to the benefit of patients and the ethical conduct of clinical trials.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Barriers to black women's participation in cancer clinical trials
    Mouton, CP
    Harris, S
    Rovi, S
    Solorzano, P
    Johnson, MS
    [J]. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 1997, 89 (11) : 721 - 727
  • [42] Patient barriers to participation in clinical trials at a community cancer center
    Geethakumari, Praveen Ramakrishnan
    Ackler, Joann R.
    Gooptu, Mahasweta
    Braitman, Leonard E.
    Tester, William J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31)
  • [43] Lacosamide monotherapy in clinical practice: A retrospective chart review
    Villanueva, V.
    Giraldez, B. G.
    Toledo, M.
    De Haan, G. J.
    Cumbo, E.
    Gambardella, A.
    De Backer, M.
    Joeres, L.
    Brunnert, M.
    Dedeken, P.
    Serratosa, J.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2018, 138 (03): : 186 - 194
  • [44] BENEFITS OF PARTICIPATION IN CLINICAL TRIALS: AN UMBRELLA REVIEW
    Bouzalmate-Hajjaj, A.
    Masso-Guijarro, P.
    Khan, K. S.
    Bueno-Cavanillas, A.
    Cano-Ibanez, N.
    [J]. GACETA SANITARIA, 2023, 37 : S205 - S206
  • [45] Benefits of Participation in Clinical Trials: An Umbrella Review
    Bouzalmate-Hajjaj, Amira
    Masso Guijarro, Paloma
    Saeed Khan, Khalid
    Bueno-Cavanillas, Aurora
    Cano-Ibanez, Naomi
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (22)
  • [46] Perceptions of barriers and facilitators to participation in clinical trials in HIV-Positive latinas:: A pilot study
    Zuniga, Maria Luisa
    Blanco, Estela
    Martinez, Paulina
    Strathdee, Steffanie A.
    Gifford, Allen L.
    [J]. JOURNAL OF WOMENS HEALTH, 2007, 16 (09) : 1322 - 1330
  • [47] Clinical Characteristics of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Chart Review Study
    Hanes, Vladimir
    Pan, Jean
    Chow, Vincent
    [J]. BLOOD, 2019, 134
  • [48] A conceptual framework for clinical trials in SLE and other multisystem diseases
    Liang, MH
    Corzillius, M
    Bae, SC
    Fortin, P
    Esdaile, JM
    Abrahamowicz, M
    [J]. LUPUS, 1999, 8 (08) : 570 - 580
  • [49] Barriers to the participation of minority ethnic/racial groups in UK clinical trials
    McClelland, Graham
    Quansah, Manuela
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 390 - 390
  • [50] Perceptions and barriers towards clinical trials participation in Asian cancer patients
    Soh, I. Peng Thomas
    Tay, Cheong Kiat Julian
    Ho, Gui Yi
    Pang, Angela
    Voon, Pei Jye
    Ling, Winnie Hui Yee
    Tan, Chee Seng
    Lee, Soo-Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)